Manara - Qatar Research Repository
10.3389_fimmu.2018.00947.pdf (500.96 kB)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

Download (500.96 kB)
journal contribution
submitted on 2024-05-29, 05:55 and posted on 2024-05-29, 13:41 authored by Remy Thomas, Ghaneya Al-Khadairi, Jessica Roelands, Wouter Hendrickx, Said Dermime, Davide Bedognetti, Julie Decock

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. In this review, we provide background information on NY-ESO-1 expression and function in normal and cancerous tissues. Furthermore, NY-ESO-1-specific immune responses have been observed in various cancer types; however, their utility as biomarkers are not well determined. Finally, we describe the immune-based therapeutic options targeting NY-ESO-1 that are currently in clinical trial. We will highlight the recent advancements made in NY-ESO-1 cancer vaccines, adoptive T cell therapy, and combinatorial treatment with checkpoint inhibitors and will discuss the current trends for future NY-ESO-1 based immunotherapy. Cancer treatment has been revolutionized over the last few decades with immunotherapy emerging at the forefront. Immune-based interventions have shown promising results, providing a new treatment avenue for durable clinical responses in various cancer types. The majority of successful immunotherapy studies have been reported in liquid cancers, whereas these approaches have met many challenges in solid cancers. Effective immunotherapy in solid cancers is hampered by the complex, dynamic tumor microenvironment that modulates the extent and phenotype of the antitumor immune response. Furthermore, many solid tumor-associated antigens are not private but can be found in normal somatic tissues, resulting in minor to detrimental off-target toxicities. Therefore, there is an ongoing effort to identify tumor-specific antigens to target using various immune-based modalities. CTAs are considered good candidate targets for immunotherapy as they are characterized by a restricted expression in normal somatic tissues concomitant with a re-expression in solid epithelial cancers. Moreover, several CTAs have been found to induce a spontaneous immune response, NY-ESO-1 being the most immunogenic among the family members. Hence, this review will focus on NY-ESO-1 and discuss the past and current NY-ESO-1 targeted immunotherapeutic strategies.

Other Information

Published in: Frontiers in Immunology
See article on publisher's website:


Open Access funding provided by the Qatar National Library.

Qatar National Research Fund (CWSP11-C-1031-16084), NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.



  • English



Publication Year

  • 2018

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Bin Khalifa University
  • Qatar Biomedical Research Institute - HBKU
  • Cancer Research Center - QBRI
  • Sidra Medicine
  • Hamad Medical Corporation
  • National Center for Cancer Care and Research - HMC

Usage metrics

    Qatar Biomedical Research Institute - HBKU



    Ref. manager